Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Novel Synthetic Membrane for Horizontal Bone Augmentation: A Case Series

13 de julho de 2026 atualizado por: Hazem Ahmed, Cairo University

Efficacy of a Novel Synthetic GBR Membrane (Inox Nanoksa G-Plus) for Horizontal Ridge Augmentation: A Case Series

The goal of this clinical study is to learn if the Inox Nanoksa G-Plus membrane works to rebuild bone in the upper or lower jaw (ridge augmentation) for adults who need dental implants but do not have enough bone width or height. It will also learn about the safety of this membrane and how patients feel after surgery.

- The main questions it aims to answer are: How much pain, swelling, and bleeding do participants experience during the first week after the bone-building surgery? How much new bone width and height does the membrane help grow, as measured on a 3D X-ray (CBCT) taken 6 months after surgery? What medical problems or side effects (such as the membrane becoming visible through the gums, infection, or graft loss) do participants experience? This is a single-treatment study; all participants will receive the same surgery using the Inox Nanoksa G-Plus membrane together with a bone graft material.

Participants will:

Have surgery to place the membrane and bone graft under their gums to rebuild their jawbone.

Take antibiotics and pain relievers, and use a special mouth rinse for about 2 weeks after surgery.

Rate their pain, swelling, and bleeding on simple scales on days 1, 3, and 7 after surgery.

Return for a checkup at 1 month and have a follow-up 3D X-ray at 6 months. Undergo a second surgery at 6 months to have dental implants placed and to evaluate the newly formed bone.

Visão geral do estudo

Descrição detalhada

Alveolar ridge resorption following tooth loss frequently results in insufficient bone width or height for ideal dental implant placement, affecting more than 40% of patients seeking implant therapy. Guided Bone Regeneration (GBR) is a well-established surgical technique for reconstructing these deficient ridges using barrier membranes. However, existing membranes present significant limitations: non-resorbable expanded polytetrafluoroethylene (e-PTFE) membranes require a second surgery for removal and carry high exposure-related complication rates, while resorbable collagen membranes often lack adequate mechanical stability and degrade unpredictably, particularly in vertical or large horizontal defects.

The Inox Nanoksa G-Plus membrane is a novel, non-resorbable hybrid nano-ceramic material containing nano-carbon and nano-zirconia within a methacrylate-based high-performance polymer matrix. While the manufacturer claims high strength, wear resistance, and biocompatibility for prosthetic applications, and recent in vitro studies have characterized its mechanical properties, no published clinical study has evaluated its safety or efficacy as a barrier scaffold for GBR in human patients. This knowledge gap forms the basis for the present investigation.

This study is designed as a prospective, single-arm, interventional clinical trial conducted at the Department of Periodontics, Faculty of Dentistry, Cairo University. No randomization or comparator group is included, as this is an initial clinical evaluation of a novel device. All eligible and consenting participants will receive the same standardized intervention.

Study Population: Systemically healthy adult patients (ASA class I or II), aged 18 years or older, presenting with partial edentulism in the maxilla or mandible and requiring horizontal (residual ridge width < 5 mm) or vertical (residual ridge height < 8 mm above vital structures) ridge augmentation prior to dental implant placement. Key exclusions include untreated periodontitis, bisphosphonate therapy, heavy active smoking (>10 cigarettes/day), and pregnancy or lactation.

Intervention: Participants will undergo a single GBR procedure using the Inox Nanoksa G-Plus membrane. The standardized surgical protocol involves a mid-crestal incision with full-thickness flap elevation, cortical perforations to enhance vascularization, placement of a particulate bone graft to fill the defect, and trimming and adaptation of the membrane to extend 3-5 mm beyond the defect margins. The membrane will be secured with titanium micro-screws, and the flap will be closed primarily with a tension-free, double-layer suture technique to achieve complete membrane coverage. Post-operatively, participants will receive prophylactic antibiotics (5-7 days), analgesics, and chlorhexidine mouth rinses for 14 days. Sutures will be removed at 10-14 days.

Study Assessments and Timeline: Participants will be followed for a total of 12 months after implant loading. The primary outcomes (patient-reported) include postoperative pain assessed via a Visual Analog Scale (VAS 0-10), as well as clinical grading of edema and bleeding, recorded on days 1, 3, and 7 post-surgery. Secondary outcomes are assessed clinically and radiographically: membrane exposure (scored 0-3 with descriptive details), infection, graft complications, and radiographic bone gain measured by Cone Beam Computed Tomography (CBCT) at 6 months post-GBR. Horizontal and vertical bone gains will be quantified in millimeters, and new bone density will be measured in Hounsfield Units (HU). At the 6-month re-entry surgery, the membrane and fixation screws will be removed, dental implants will be placed, and implant primary stability will be recorded. A final follow-up at 12 months after implant loading will evaluate implant survival and success.

Data Management and Analysis: All data will be recorded in standardized case report forms and entered into a password-protected electronic database. Statistical analysis will be performed using Medcalc software. Continuous variables will be analyzed using paired t-tests or Wilcoxon signed-rank tests for pre- versus post-operative comparisons, and repeated measures ANOVA for multiple time points. Categorical data will be presented as frequencies and percentages. A p-value ≤ 0.05 will be considered statistically significant. The sample size of 12 participants was calculated to estimate the mean bone gain with adequate precision, accounting for an anticipated 20% dropout rate.

Ethics and Dissemination: The study protocol has received ethical approval from the Research Ethics Committee of the Faculty of Oral and Dental Medicine, Cairo University. All participants will provide written informed consent in Arabic after receiving a full explanation of the procedures, benefits, risks, and alternative treatments. Participant confidentiality will be strictly maintained. The results of this study will be submitted for publication in a peer-reviewed dental journal and presented at academic conferences, regardless of the outcome direction, to contribute evidence on the clinical applicability of synthetic high-performance polymer membranes in bone regeneration.

Tipo de estudo

Intervencional

Inscrição (Estimado)

12

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Cairo Governorate
      • Cairo, Cairo Governorate, Egito, 11553
        • Department of Periodontics, Faculty of Dentistry, Cairo University
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Partial edentulism in the maxilla or mandible requiring single or multiple implant-supported restorations.
  • Insufficient bone volume for standard implant placement, defined as:

    • Horizontal defect: residual ridge width < 5 mm at the intended implant site, OR
    • Vertical defect: residual ridge height < 8 mm above vital structures (mandibular canal, maxillary sinus, nasal floor).
  • Healthy oral mucosa with no signs of active infection or inflammation at the defect site.
  • Systemically healthy or with well-controlled medical conditions (American Society of Anesthesiologists - ASA class I or II).

Exclusion Criteria:

  • Untreated periodontitis or active peri-implant disease.
  • Current or previous treatment with intravenous bisphosphonates (or oral bisphosphonates for > 3 years).
  • Severe immunosuppression or chronic systemic corticosteroid therapy (> 10 mg/day prednisolone for > 3 months).
  • Active smoking (> 10 cigarettes per day). Smoking cessation for at least 2 weeks before surgery is required; heavy smokers may be excluded.
  • Pregnant or lactating women.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Nanoksa G-Plus GBR Group
Participants with horizontal or vertical alveolar ridge deficiency undergo guided bone regeneration using the Inox Nanoksa G-Plus membrane in conjunction with a particulate bone graft. All participants receive the same standardized surgical protocol.
A sterile, non-resorbable hybrid nano-ceramic membrane composed of a methacrylate-based high-performance polymer matrix reinforced with nano-zirconia and nano-carbon. It is supplied as a pre-formed sheet (thickness ~0.2-0.3 mm) that can be cut and shaped intraoperatively. The membrane serves as a barrier scaffold to exclude soft tissue cells and allow osteogenic cells to populate the bone defect during guided bone regeneration.
A commercially available particulate bone graft material (xenograft, allograft, or synthetic) selected based on defect type and surgeon preference. The graft is hydrated with sterile saline or autologous blood and packed into the defect to fill the volume and provide a scaffold for new bone formation.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Postoperative Pain
Prazo: Days 1, 3, and 7 post-surgery
Pain intensity measured using a Visual Analog Scale (VAS) where 0 = no pain and 10 = worst imaginable pain. Patients record pain at rest and during function.
Days 1, 3, and 7 post-surgery
Postoperative Edema/Swelling
Prazo: Days 1, 3, and 7 post-surgery
Clinically graded by a blinded assessor using a 4-point scale: 0 = none, 1 = mild (localized, intraoral only), 2 = moderate (visible extraoral swelling, no functional impairment), 3 = severe (significant facial swelling with functional impairment).
Days 1, 3, and 7 post-surgery
Postoperative Bleeding
Prazo: Days 1, 3, and 7 post-surgery
Clinically assessed at the surgical site using a 4-point scale: 0 = none, 1 = mild (oozing, stops spontaneously), 2 = moderate (requires gauze change or local pressure), 3 = severe (requires surgical intervention).
Days 1, 3, and 7 post-surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Horizontal Bone Gain
Prazo: 6 months post-GBR (T2) vs. Baseline (T0)
Change in ridge width measured on CBCT at 6 months compared to baseline. Measured at 1 mm, 3 mm, and 5 mm apical to the ridge crest; the mean of these three measurements is used. Gain = (width at T2) - (width at T0).
6 months post-GBR (T2) vs. Baseline (T0)
Vertical Bone Gain
Prazo: 6 months post-GBR (T2) vs. Baseline (T0)
Change in ridge height measured on CBCT at 6 months compared to baseline. Measured from the crest to the most apical point of the defect in the center of the defect. Gain = (height at T2) - (height at T0).
6 months post-GBR (T2) vs. Baseline (T0)
Membrane Exposure
Prazo: Throughout healing period (up to 6 months post-GBR)
Visible exposure of the Nanoksa G-Plus membrane through the oral mucosa during healing. Scored as: 0 = none, 1 = pinpoint < 2 mm no suppuration, 2 = partial 2-5 mm with/without mild inflammation, 3 = complete > 5 mm OR any exposure with suppuration/infection/graft loss. Time of first exposure and management are also recorded.
Throughout healing period (up to 6 months post-GBR)
New Bone Density
Prazo: 6 months post-GBR (T2) vs. Baseline (T0)
Bone density measured by CBCT densitometry in Hounsfield Units (HU) at the augmented site at 6 months compared to baseline.
6 months post-GBR (T2) vs. Baseline (T0)
Patient Satisfaction
Prazo: 6 months post-GBR (T2)
Overall treatment experience assessed using a Likert scale (1-5).
6 months post-GBR (T2)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de setembro de 2026

Conclusão Primária (Estimado)

1 de março de 2027

Conclusão do estudo (Estimado)

1 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

8 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de julho de 2026

Primeira postagem (Real)

14 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

14 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever